CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
8-K, 1996-12-12
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Previous: PENN NATIONAL GAMING INC, 8-K, 1996-12-12
Next: ALCO CAPITAL RESOURCE INC, 424B2, 1996-12-12



                     SECURITIES AND EXCHANGE COMMISSION 
 
                   Washington, D. C.   20549 
 
                         FORM 8-K
 
            Current Report Pursuant to Section 13 or 15(d) 
              of The Securities Exchange Act of 1934 
 
 
Date of Report: December 12, 1996      Commission file number:  0-24930 
 
       CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT, INC. 
    (Exact name of registrant as specified in its charter) 
 
 
        Florida                                       59-3029743 
  (State or other jurisdiction               IRS Employer Identification No.  
   of incorporation or organization) 
 
 
    3713 S.W. 42nd Avenue, Suite 3, Gainesville, Florida, 32608-6581 
     (Address of principal executive offices)             (Zip Code) 
 
 
    Registrant's telephone number, including area code:   904-375-6822 
  
<PAGE> 
 
 

Item 4 - Changes in Registrant's Certifying Accountant

(a) On December 6, 1996, Registrant engaged the accounting firm of Davis, Monk
& Co. as independent accountants for the Registrant for 1996.  The work of
James Moore & Co. was terminated on December 6, 1996.  The termination of
James Moore & Co. and the engagement of Davis, Monk & Co. was approved by
Registrant's Board of Directors.

(b) During the two most recent fiscal years ended December 31, 1995, there
have been no disagreements with James Moore & Co. on any matter of
accounting principles or practices, financial statement disclosure or
auditing scope or procedure or any reportable events.

(c) James Moore & Co.'s report on the financial statements for the past
two years ended December 31, 1995, contained no adverse opinion or 
disclaimer of opinion and was not qualified or modified as to uncertainty,
audit scope or accounting principles.

(d) The Registrant has requested that James Moore & Co. furnish it with a
letter addressed to the Securities and Exchange Commission stating whether
or not it agrees with the statements made by the Registrant in response
to this Item 4 and if not, stating the respects in which it does not agree.
Registrant delivered a copy of this Form 8-K Report to James Moore & Co.
on December 12, 1996.  The Registrant will file by amendment as an exhibit
to this Form 8-K Report, a copy of such letter when it is received.


<PAGE> 

 
Item 14.  Exhibits, Financial Statement Schedules, and Reports on Form 8-K 
 
Exhibit     Description                                             Page 



(1) Underwriting agreement                                           None

(2) Plan of acquisition, reorganization, 
    arrangement, liquidation or succession                           None

(4) Instruments defining the rights of 
    security holders, including debentures                           None

(16) Letter re change in certifying accountant                       None

(17) Letter re director resignation                                  None

(21) Other documents or statements to security holders               None

(24) Consents of experts and counsel                                 None

(25) Power of attorney                                               None

(28) Additional exhibits                                             None



<PAGE> 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the 
registrant has duly caused this report to be signed on its behalf by the  
undersigned thereunto duly authorized. 
 
 
Dated:  December 12, 1996 
 
                                          C. E. RICK STRATTAN 
                                          C. E. RICK STRATTAN 
                                          President, Chief Executive Officer, 
                                          Chief Financial Officer 






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission